Description: Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Home Page: ainos.com
AIMD Technical Analysis
8880 Rio San Diego Drive
San Diego,
CA
92108
United States
Phone:
858 869 2986
Officers
| Name | Title |
|---|---|
| Mr. Chun-Hsien Tsai | Chairman of Board, Pres & CEO |
| Ms. Hui-Lan Wu | Chief Financial Officer |
| Mr. Lawrence Kennedy Lin | Exec. VP of Operations |
| Mr. John Junyong Lee Esq. | Chief Legal Counsel, Corp. Counsel & Sec. |
| Mr. Chih-Heng Lu | Corp. Sec. of Board & Director of Corp. Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3571 |
| Price-to-Sales TTM: | 5.3859 |
| IPO Date: | 2013-11-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 34 |